Dr. Hassan has played pivotal role in validating the tumor differentiation antigen mesothelin as a target for cancer therapy and development of mesothelin targeted immunotherapy. This work has laid the foundation for several mesothelin directed agents that he is evaluating in the clinic for treatment of mesothelioma, lung and pancreatic cancer. His clinical trials using an anti-mesothelin immunotoxin has shown major tumor responses in patients with mesothelioma. Ongoing efforts are directed to exploiting this approach for treatment of lung and pancreatic cancer.
Get help from Mesothelioma Doctors & Hospitals.